Table 1.
Patients' characteristics showing AP-2 protein expression
| AP-2 (α and β isoforms) | AP-2 (α isoform) | |||||
|---|---|---|---|---|---|---|
| Variable | Positive (%) | Negative (%) |
χ 2 (P-value) |
Positive (%) | Negative (%) |
χ 2 (P-value) |
| Patients age | ||||||
| <40 | 16 (6.0) |
69 (7.6) |
2.381 (0.497) | 45 (8.7) |
35 (8.3) |
0.225 (0.973) |
| 40-50 | 69 (25.7) | 244 (26.9) | 160 (30.8) | 134 (31.7) | ||
| 51-60 | 79 (29.5) | 285 (31.4) | 169 (32.6) | 133 (31.4) | ||
| >60 | 104 (38.8) | 310 (34.1) | 145 (27.9) | 121 (28.6) | ||
| Primary tumour size | ||||||
| ≤ 1.5 cm | 112 (41.6) | 274 (30.3) | 12.125 (<0.001) | 252 (48.4) |
215 (51.6) | 0.943 (0.332) |
| >1.5 cm | 157 (58.4) | 631 (69.7) | 269 (51.6) | 202 (48.4) | ||
| Lymph node Stage | ||||||
| 1 | 177 (65.8) | 554 (61.3) | 5.382 (0.068) | 331 (63.5) | 249 (59.6) | 1.949 (0.377) |
| 2 | 78 (29.0) |
263 (29.1) | 143 (27.4) | 132 (31.6) | ||
| 3 | 14 (5.2) |
87 (9.6) |
47 (9.0) |
37 (8.8) |
||
| Grade | ||||||
| 1 | 60 (22.3) |
137 (15.2) | 43.672 (<0.001) | 66 (12.7) | 73 (17.5) |
4.476 (0.107) |
| 2 | 124 (46.1) | 274 (30.3) | 160 (30.7) | 126 (30.2) | ||
| 3 | 85 (31.6) |
493 (54.5) | 295 (56.6) | 218 (52.3) | ||
| NPI | ||||||
| Poor | 25 (9.3) |
224 (24.8) | 35.333 (<0.001) | 85 (16.3) |
84 (20.1) |
3.574 (0.167) |
| Moderate | 130 (48.3) | 517 (57.1) | 303 (58.2) | 219 (52.4) | ||
| Good | 114 (42.4) | 164 (18.1) | 133 (25.5) | 115 (27.5) | ||
| Development of Distant Metastasis | ||||||
| No | 193 (73.1) | 611 (68.0) | 2.528 (0.112) | 341 (66.1) | 302 (71.7) | 3.436 (0.064) |
| Positive | 71 (26.9) |
288 (32.0) | 175 (33.9) | 119 (28.3) | ||
| Development of Recurrence | ||||||
| No | 165 (62.5) | 504 (56.4) | 3.069 (0.08) | 294 (57.8) | 248 (60.6) | 1.969 (0.374) |
| Positive | 99 (37.5) |
389 (43.6) | 215 (42.2) | 161 (39.4) | ||
| Vascular invasion | ||||||
| No | 168 (63.2) | 495 (55.0) | 6.674 (0.036) | 286 (55.5) | 220 (52.4) | 0.949 (0.622) |
| Probable | 21 (7.9) |
109 (12.1) | 61 (11.8) |
52 (12.4) |
||
| Definite | 77 (28.9) |
296 (32.9) | 168 (32.6) | 148 (35.2) | ||
| Tumour type | ||||||
| Ductal/NST | 129 (49.0) | 551 (61.5) | 29.22 (<0.001) | 326 (63.9) | 252 (60.3) | 15.31 (0.032) |
| Lobular | 45 (17.1) |
74 (8.3) |
46 (9.0) |
35 (8.4) |
||
| Tubular and Tubular mixed | 61 (23.2) |
178 (19.9) | 81 (15.9) |
90 (21.5) |
||
| Medullary | 4 (1.5) |
29 (3.2) |
22 (4.3) |
7 (1.7) |
||
| Other special types* | 8 (3.0) |
12 (1.3) |
7 (1.4) |
7 (1.7) |
||
| Mixed** | 16 (6.1) |
47 (5.2) |
26 (5.1) |
24 (5.7) |
||
| Menopausal status | ||||||
| Premenopausal | 103 (38.4) | 355 (39.1) | 0.038 (0.845) | 212 (40.8) | 171 (40.4) | 0.017 (0.896) |
| Postmenopausal | 165 (61.6) | 553 (60.9) | 307 (59.2) | 252 (59.6) | ||
Two different AP-2 antibodies were used; one recognised AP-2α and β isoforms while the other recognised only the AP-2α isoform. *Includes Mucoid, invasive cribriform and invasive papillary carcinoma. **Includes ductal/No special type (NST) mixed with lobular or special types. NPI = Nottingham Prognostic Index.